Xofluza

Xofluza · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 19, 2027

~1.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (54)

Apr 21, 2041formulationUS 11925648
Apr 21, 2041formulationUS 11925648
Apr 21, 2041formulationUS 11925648
Oct 9, 2039formulationUS 12064438
Oct 9, 2039formulationUS 12064438
Oct 9, 2039formulationUS 12064438
Sep 25, 2038formulationUS 11261198
Sep 25, 2038formulationUS 11261198
Sep 25, 2038formulationUS 11261198
Sep 25, 2038formulationUS 11261198
Sep 25, 2038formulationUS 11261198
Sep 25, 2038formulationUS 11261198
Aug 9, 2037compositionUS 10759814
Aug 9, 2037compositionUS 10759814
Aug 9, 2037compositionUS 10759814
Aug 9, 2037compositionUS 10759814
Aug 9, 2037compositionUS 10759814
Aug 9, 2037compositionUS 10759814
Aug 9, 2037method-of-use (U-3000)US 11306106
Aug 9, 2037method-of-use (U-2816)US 11306106
Aug 9, 2037method-of-use (U-3000)US 11306106
Aug 9, 2037method-of-use (U-3000)US 11306106
Aug 9, 2037method-of-use (U-3000)US 11306106
Aug 9, 2037method-of-use (U-3000)US 11306106
Apr 27, 2036compositionUS 10392406
Apr 27, 2036compositionUS 10392406
Apr 27, 2036compositionUS 10392406
Apr 27, 2036compositionUS 10392406
Apr 27, 2036compositionUS 10392406
Apr 27, 2036compositionUS 10392406
Apr 27, 2036method-of-use (U-3000)US 10633397
Apr 27, 2036method-of-use (U-2816)US 10633397
Apr 27, 2036method-of-use (U-2816)US 10633397
Apr 27, 2036method-of-use (U-3000)US 10633397
Apr 27, 2036method-of-use (U-3000)US 10633397
Apr 27, 2036method-of-use (U-2816)US 10633397
Oct 24, 2032compositionUS 8987441
Oct 24, 2032compositionUS 8987441
Oct 24, 2032compositionUS 8987441
Oct 24, 2032compositionUS 8987441
Oct 24, 2032compositionUS 8987441
Oct 24, 2032compositionUS 8987441
May 5, 2031formulationUS 89277104.8y
May 5, 2031formulationUS 89277104.8y
May 5, 2031formulationUS 89277104.8y
May 5, 2031formulationUS 89277104.8y
May 5, 2031formulationUS 89277104.8y
May 5, 2031formulationUS 89277104.8y
Jun 14, 2030formulationUS 98158353.9y
Jun 14, 2030formulationUS 98158353.9y
Jun 14, 2030formulationUS 98158353.9y
Jun 14, 2030formulationUS 98158353.9y
Jun 14, 2030formulationUS 98158353.9y
Jun 14, 2030formulationUS 98158353.9y

FDA exclusivities (4)

Dec 19, 2027M-187Method (3y)1.5y
Dec 19, 2027M-187Method (3y)1.5y
Dec 19, 2027M-187Method (3y)1.5y
Dec 19, 2027M-187Method (3y)1.5y

baloxavir marboxil

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

Patent cliff

patents (54)

FDA exclusivities (4)

Trials studying baloxavir marboxil